ArticleOncotarget2014
SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma.
Article in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Targeting Hsp70 Immunosuppressive Signaling Axis with Lipid Nanovesicles: A Novel Approach to Treat Pancreatic Cancer.Cancers · 2025Article
- Pooled genetic screens to identify vulnerabilities in TERT-promoter-mutant glioblastoma.Oncogene · 2023Article
- Review
- SapC-DOPS as a Novel Therapeutic and Diagnostic Agent for Glioblastoma Therapy and Detection: Alternative to Old Drugs and Agents.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Accumulation of saposin in dystrophic neurites is linked to impaired lysosomal functions in Alzheimer's disease brains.Molecular neurodegeneration · 2021Article
- Targeting of elevated cell surface phosphatidylserine with saposin C-dioleoylphosphatidylserine nanodrug as individual or combination therapy for pancreatic cancer.World journal of gastrointestinal oncology · 2021Review
- Reuse of Molecules for Glioblastoma Therapy.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Lysosomes in glioblastoma: pump up the volume.Cell cycle (Georgetown, Tex.) · 2020Review
- Biotherapy of Brain Tumors with Phosphatidylserine-Targeted Radioiodinated SapC-DOPS Nanovesicles.Cells · 2020Article
- Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- SapC-DOPS - a Phosphatidylserine-targeted Nanovesicle for selective Cancer therapy.Cell communication and signaling : CCS · 2020Review
- Enhanced phosphatidylserine-selective cancer therapy with irradiation and SapC-DOPS nanovesicles.Oncotarget · 2019Article
- Beyond Alkylating Agents for Gliomas: Quo Vadimus?American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2017Review
- Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Optical and nuclear imaging of glioblastoma with phosphatidylserine-targeted nanovesicles.Oncotarget · 2016Article
- "Eat me" imaging and therapy.Advanced drug delivery reviews · 2016Review
- Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity.Disease models & mechanisms · 2016Article
- PIG7 promotes leukemia cell chemosensitivity via lysosomal membrane permeabilization.Oncotarget · 2016Article
- Variation in human cancer cell external phosphatidylserine is regulated by flippase activity and intracellular calcium.Oncotarget · 2015Article
- Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles.Translational oncology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 1 country.
Funding
Abstract
SapC-DOPS is a novel nanotherapeutic that has been shown to target and induce cell death in a variety of cancers, including glioblastoma (GBM). GBM is a primary brain tumor known to frequently demonstrate resistance to apoptosis-inducing therapeutics. Here we explore the mode of action for SapC-DOPS in GBM, a treatment being developed by Bexion Pharmaceuticals for clinical testing in patients. SapC-DOPS treatment was observed to induce lysosomal dysfunction of GBM cells characterized by decreased glycosylation of LAMP1 and altered proteolytic processing of cathepsin D independent of apoptosis and autophagic cell death. We observed that SapC-DOPS induced lysosomal membrane permeability (LMP) as shown by LysoTracker Red and Acridine Orange staining along with an increase of sphingosine, a known inducer of LMP. Additionally, SapC-DOPS displayed strong synergistic interactions with the apoptosis-inducing agent TMZ. Collectively our data suggest that SapC-DOPS induces lysosomal cell death in GBM cells, providing a new approach for treating tumors resistant to traditional apoptosis-inducing agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.